



University of Dundee

Heterogeneity in phenotype, disease progression and drug response in type 2 diabetes

Thakarakkattil Narayanan Nair, Anand; Wesolowska-Andersen, Agata; Brorsson, Caroline A.; Lathika Rajendrakumar, Aravind; Hapca, Simona; Gan, Sushrima

Published in:
Nature Medicine

DOI:
[10.1038/s41591-022-01790-7](https://doi.org/10.1038/s41591-022-01790-7)

Publication date:
2022

Document Version
Peer reviewed version

[Link to publication in Discovery Research Portal](#)

Citation for published version (APA):

Thakarakkattil Narayanan Nair, A., Wesolowska-Andersen, A., Brorsson, C. A., Lathika Rajendrakumar, A., Hapca, S., Gan, S., Dawed, A. Y., Donnelly, L. A., McCrimmon, R., Doney, A. S. F., Palmer, C. N. A., Mohan, V., Anjana, R. M., Hattersley, A. T., Dennis, J. M., & Pearson, E. R. (2022). Heterogeneity in phenotype, disease progression and drug response in type 2 diabetes. *Nature Medicine*, 28, 982-988. <https://doi.org/10.1038/s41591-022-01790-7>

General rights

Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Supplementary Table 1: Phenotypic characteristics of the study population in this analysis.

Variables	Tayside Scotland (SCI-DC) (N=23137)	UK Biobank (N=7332)	ADOPT trial (N=4150)
	Mean (SD)/N (%)	Mean (SD)/N (%)	Mean (SD)/N (%)
Males	13007 (56.2)	4359 (59.5)	2383 (57.4)
Age at diagnosis (year)	63.2 (11.7)	61.8 (7.6)	56.5 (10.0)
HDL-c (mmol/L)	1.2 (0.3)	1.2 (0.3)	1.2 (0.3)
Total cholesterol (mmol/L)	5.0 (1.2)	5.1 (1.2)	5.3 (1.0)
Triglycerides (mmol/L)	2.4 (1.5)	2.2(1.3)	2.1 (1.3)
HbA1c (%)	7.9 (1.9)	7.5 (1.8)	7.3 (0.9)
BMI (Kg/m ²)	32.2 (6.5)	31.8 (5.9)	32.1 (6.2)
SBP (mm of Hg)	138.8 (18.5)	136.5 (15.8)	132.8 (15.4)
DBP (mm of Hg)	80.2 (10.8)	80.1 (9.8)	79.6 (8.7)
ALT (IU/L)	35.1 (22.2)	36.6 (20.9)	26.7 (14.2)
Creatinine (mmol/L)	79.1 (22.5)	83.1(18.1)	71.1 (16.4)
C-peptide (nmol/l) (n=3604)	2.0(1.1)	-	-
Adiponectin (ng/ml) (n=965)	4552.3(3051.3)	-	-
Leptin (ng/ml) (n=742)	17549.3(15208.3)	-	-
HOMA2-B	-	-	72.6 (28.6)
HOMA2-IR	-	-	2.9 (1.2)

Supplementary Table 1 shows mean and standard deviation phenotypic variables of the study participants (in Scottish, UKBB and ADOPT data) at the time of T2D diagnosis (C-peptide, adiponectin and leptin measurements were not available at the time of diagnosis in Scottish data)

Supplementary table 2: Summary of GAM models predicting DDRTree Dimension1 and Dimension 2, fitted with cubic regression splines.

Variables	GAM for DDRTree Dimension1 (adj.R²=79.5%)				GAM for DDRTree Dimension2 (adj.R²=86.0%)			
Parametric Coefficient	Estimate	Std. Error	P value		Estimate	Std. Error	P value	
<i>Sex</i>	-0.071	0.004	<0.0001		0.218	0.003	<0.0001	
Smooth terms	edf	Ref.df	F	P value	edf	Ref.df	F	P value
<i>Age at diagnosis (year)</i>	7.72	8.40	1039.40	<0.0001	3.04	3.82	134.16	<0.0001
<i>HDL-c (mmol/L)</i>	7.26	8.14	696.05	<0.0001	8.53	8.90	2786.68	<0.0001
<i>Total cholesterol (mmol/L)</i>	5.15	6.64	377.70	<0.0001	6.39	7.53	674.20	<0.0001
<i>Triglycerides (mmol/L)</i>	7.81	8.57	1255.44	<0.0001	7.48	8.36	925.80	<0.0001
<i>HbA1c (%)</i>	7.39	8.21	497.27	<0.0001	4.89	5.91	95.84	<0.0001
<i>BMI (Kg/m²)</i>	7.76	8.55	476.17	<0.0001	5.48	6.65	818.97	<0.0001
<i>SBP (mm of Hg)</i>	6.40	7.58	603.05	<0.0001	6.51	7.67	1437.75	<0.0001
<i>DBP (mm of Hg)</i>	7.40	8.37	557.81	<0.0001	8.41	8.89	1139.93	<0.0001
<i>ALT (IU/L)</i>	7.18	8.00	368.41	<0.0001	6.83	7.71	109.21	<0.0001
<i>Creatinine (mmol/L)</i>	2.21	3.54	34.79	<0.0001	4.17	5.12	627.07	<0.0001

Supplementary table 3: Summary of competing risk models constructed with continuous covariates for diabetes outcomes (Insulin Initiation, MACE, CKD and DR) . Table shows sHR (sub Hazard Ratios) and 95% CI with p values generated from Fine Gray models of competing risk analysis.

Variables	Competing risk models							
	Time to Insulin		Time to MACE		Time to CKD		Time to DR	
N	22595		18239		19956		22759	
Event of Interest (n(%))	3954 (17.5)		3261 (17.9)		3160 (15.8)		540 (2.4)	
Competing event (n(%))	3627 (16.1)		1483 (8.1)		2320 (11.6)		4131 (18.2)	
	sHR 95% CI	P value	sHR 95% CI	P value	sHR 95% CI	P value	sHR 95% CI	P value
Sex	0.80 (0.74-0.86)	<0.0001	1.24 (1.14-1.35)	<0.0001	0.35 (0.31-0.39)	<0.0001	1.28 (1.05-1.58)	<0.01
Age at diagnosis (year)	0.96 (0.96-0.96)	<0.0001	1.02 (1.02-1.03)	<0.0001	1.06 (1.05-1.06)	<0.0001	***	
HDL-c (mmol/L)*	-		0.61 (0.52-0.72)	<0.0001	-		-	
Total cholesterol (mmol/L)	0.91 (0.88-0.94)	<0.0001	-		-		***	
Triglycerides (mmol/L)*	1.21 (1.13-1.30)	<0.0001	-		1.13 (1.03-1.24)	<0.0001	-	
HbA1c (%)	**		1.02 (1.00-1.03)	0.03	1.06 (1.03-1.08)	<0.0001	1.22 (1.18-1.22)	<0.0001
BMI (Kg/m ²)	***		1.01(1.00-1.02)	0.0001	***		***	
SBP (mm of Hg)	-		***		1.01 (1.01-1.01)	<0.0001	1.01 (1.01-1.01)	<0.0001
DBP (mm of Hg)	-		***		-		-	
ALT (IU/L)*	-		0.77 (0.74-0.84)	<0.0001	0.81 (0.75-0.88)	<0.0001	0.90 (0.87-0.95)	<0.0001
Creatinine (mmol/L)*	1.01 (1.00-1.01)	<0.0001	1.42 (1.18-1.71)	0.0001	**		-	
Year of Diagnosis (Year)	0.97 (0.97-0.98)	<0.0001	0.96 (0.95-0.96)	<0.0001	0.96 (0.95-0.97)	<0.001	0.91 (0.89-0.93)	
Statin use	-		1.24 (1.12-1.36)	<0.0001	0.86 (0.79-0.95)	<0.0001	0.64 (0.50-0.83)	<0.0001
Antihypertensive medication	0.84 (0.78-0.91)	<0.0001	1.11 (1.03-1.14)	<0.01	0.76 (0.70-0.82)	<0.0001	0.56 (0.46-0.68)	0.001

*Log transformed, **Stratified analysis, ***Spline function, - Nonsignificant effect

Supplementary Table 4: Performance of competing risk models, ROC AUC at 5 years follow up.

Model	ROC AUC (95% CI) 9 continuous clinical variables + age and sex+ drugs + year of T2D Diagnosis Internal validation	ROC AUC (95% CI) 9 continuous clinical variables+ age and sex+ drugs + year of T2D Diagnosis External validation	ROCAUC (95% CI) DDRTree Dimensions + age and sex	ROCAUC (95% CI) DDRTree Dimensions (Spline) + age and sex	ROCAUC (95% CI) 9 continuous clinical variables + DDRTree Dimensions + Age and Sex+ drugs + year of T2D Diagnosis
Insulin Initiation model	0.72 (0.71-0.73)	0.74 (0.71-0.77)	0.65 (0.64-0.67)	0.66 (0.64-0.67)	0.74 (0.72-0.75)
CKD Model	0.78 (0.77-0.80)	0.73 (0.70-0.76)	0.74 (0.73-0.76)	0.75 (0.73-0.76)	0.83 (0.82-0.85)
DR Model	0.72 (0.69-0.75)	--	0.58 (0.55-0.62)	0.60 (0.56-0.63)	0.72 (0.69-0.75)
MACE model	0.68 (0.66-0.69)	0.65 (0.62-0.68)	0.66 (0.65-0.68)	0.66 (0.65-0.68)	0.68 (0.66-0.69)

**drugs: statin and antihypertension drugs at the time of T2D diagnosis*

Supplementary Table 5: ICD codes used to identify MACE from SMR and GRO database in Tayside and Fife data.

ICD 10 / ICD 9 codes	
ICD 10 codes	I2000,I2001,I2002,I2009,I201,I208,I209,I21,I21.A1,I21.A9 ,I210,I2100,I2101,I2109,I211 ,I2110,I2111, I2119,I212 ,I2120,I2121,I213 ,I2130,I2139,I214,I2140,I219,I2190,I2191,I2199,I22 ,I229, I220,I2201, I221 ,I2210,I2211,I228 , I2280,I2281,I229,I2290,I2291,I23 ,I230 , I231 ,I232,I232 , I233 ,I234 , I238,I240,I241,I248,I249,I252,I25,I250,I251,I252 ,I253,I254 ,I255 ,I256 ,I258,I259,I46,I460,I461,I469,
ICD 9 codes	410,4101,4102,4103,4104,4105,4106,4107,4108,4109,411,4110,4111,4118,412,4297, 413,4130,4131,4139,4141,415,4150,4151
CABG_ICD10_OPCS	K40,K401,K402,K403,K404,K408,K409,K41,K411,K412,K413,K414,K418,K419,K42,K421, K422,K423,K424,K428,K429,K43,K431,K432,K433,K434,K438,K439,K44,K441,K442,K448, K449,K45,K451,K452,K453,K454,K455,K456,K458,K459,K46,K461,K462,K463,K464,K465, K468,K469,K47,K471,K472,K473,K474,K475,K478,K479,K48,K481,K482,K483,K484,K488,K489
CABG_ICD9_OPCS	304,3041,3042,3043,3044.
PCI_ICD10_OPCS	K49,K491,K492,K493,K494,K498,K499,K50,K501,K502,K503,K504,K508,K509,K75,K751, K752,K753,K754,K758,K759.
PCI_ICD9_OPCS	884,8841,8842,8843,8844.